July 10, 2024


Merck Animal Health completes acquisition of Elanco's aqua business


Merck Animal Health, known as MSD Animal Health outside of the US and Canada, a division of Merck & Co, Rahway, New Jersey, US, announced the completion of its acquisition of the aqua business of Elanco Animal Health Incorporated.


The completion of this acquisition bolsters Merck Animal Health's position in the aqua industry with a comprehensive approach to promote fish health, welfare and sustainability in aquaculture, conservation, and fisheries.


"With the completion of this acquisition, we are well positioned within the aquaculture industry with a robust and comprehensive portfolio across warm water, cold water, vaccines, anti-parasitic treatments, water supplements and nutrition," said Rick DeLuca, president, Merck Animal Health. "We are excited to welcome our new colleagues to Merck Animal Health and we look forward to working together, driven by our common purpose of the Science of Healthier Animals."


As a result of the acquisition, Merck Animal Health now owns innovative products such as CLYNAV, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease and IMVIXA, an anti-parasitic sea lice treatment and water treatment products for warm water production, complementing Merck Animal Health's vaccine portfolio.


The increasing use of medicines and vaccines, nutritionals and supplements for aquatic species is driven by the growing demand for protein and food safety, ensuring a supply of quality food and protecting public health.


-      Merck Animal Health